Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Elysia Bio is a private North Carolina agricultural biotechnology company developing genetically engineered feed crops for livestock. Its approach is to embed beneficial traits directly into common pasture, silage, and grain crops so farmers can use improved feed without changing their existing operating practices or relying on feed additives or drugs. The company is focused on reducing enteric methane emissions from cattle and other ruminants while also improving herd productivity and farm economics. Elysia appears to be an early-stage platform company centered on crop biotechnology for climate and animal agriculture applications, with independent cattle trials for its first product planned for 2026.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Elysia Bio.